All Deals
March 19, 2025 - Deals
257 Secures $9.2M Seed Funding Led By F2 Venture Capital And Notable Investors
257, a NYC-based software and AI company focused on the residential energy market, raised $9.2M in seed funding led by F2 Venture Capital, with participation from Mike Fallquist (Founder & CEO of Crius Energy, Co-Founder & CEO of Energywell), Jeff Hammerbacher (Co-Founder & Co-CEO of Open Athena, founder of Cloudera), Otto von Troschke (Co-Founder of SUSI), and Gil Golan (former GM CTO). Led by Co-Founder & CEO Scott Rosenberg and Co-Founder & CTO Tal Chalozin, 257 uses AI and proprietary energy profiles to accelerate the adoption of residential energy products, offering solutions like 257 Insights, 257 Audiences, and 257 Engage to improve customer engagement and decision-making.
INVESTORS: F2 Venture Capital, Mike Fallquist, Jeff Hammerbacher, Otto von Troschke & Gil Golan
AMOUNT: $9,200,000
HQ: #NewYork #NY #NewYorkCity #NYC
#VentureCapital #257 #F2VentureCapital #MikeFallquist #JeffHammerbacher #OttovonTroschke #GilGolan #ScottRosenberg #TalChalozin #TradedVC
More Deals
View All
Colossal Biosciences In Talks For Funding Round Targeting $23 Billion ValuationColossal Biosciences, the de-extinction biotech startup known for its efforts to recreate the woolly mammoth and other extinct species, is reportedly in talks to raise new funding at a valuation of roughly $23 billion–$24 billion, according to Axios. The potential raise would mark a significant jump for the five-year-old company, with investors valuing not only its genetic-engineering programs but also its broader genomics, reproductive technology, conservation, and intellectual property platform. Colossal has begun generating revenue through conservation technology sales and technology spinouts, including Astromech, an AI-driven predictive modeling company, and Form Bio, a computational biology platform, expanding its value beyond de-extinction efforts.
FOUNDERS: Ben Lamm & George Church
TARGET VALUATION: $23,000,000,000
HQ: Dallas, Texas
#VentureCapital #ColossalBiosciences #BenLamm #GeorgeChurch #TradedVC